Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $314,400.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00. Following the completion of the transaction, the insider directly owned 334,786 shares in the company, valued at $7,017,114.56. This trade represents a 4.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Brian Daniel Webster also recently made the following trade(s):

• On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.04, for a total transaction of $300,600.00.
• On Tuesday, March 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.27, for a total transaction of $304,050.00.
• On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.60, for a total transaction of $384,000.00.

Kestra Medical Technologies Price Performance

Shares of KMTS stock traded down $0.23 during mid-day trading on Monday, hitting $19.59. The company had a trading volume of 276,736 shares, compared to its average volume of 323,287. Kestra Medical Technologies, Ltd. has a 52-week low of $13.25 and a 52-week high of $30.00. The stock’s 50 day moving average price is $20.73 and its 200-day moving average price is $23.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The company has a market capitalization of $1.14 billion, a P/E ratio of -4.95 and a beta of 0.82.

Kestra Medical Technologies (NASDAQ:KMTS) last released its earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The company had revenue of $24.55 million during the quarter. The company’s quarterly revenue was up 62.7% on a year-over-year basis. Equities research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Finally, The Goldman Sachs Group decreased their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $27.40.

Institutional Investors Weigh In On Kestra Medical Technologies

Hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC purchased a new stake in Kestra Medical Technologies during the fourth quarter valued at $31,000. Russell Investments Group Ltd. raised its stake in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Kestra Medical Technologies during the third quarter valued at $48,000. Daiwa Securities Group Inc. purchased a new stake in Kestra Medical Technologies during the fourth quarter valued at $72,000. Finally, BNP Paribas Financial Markets raised its stake in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.